REGN250117P665000
- 2.64
- -2.66-50.19%
Regeneron Pharmaceuticals Newsroom
Jim Cramer Says He Supports Healthcare Stocks for Their Long-term Value
Regeneron Pharmaceuticals Shares Are Trading Lower After Citigroup Cut Its Price Target on the Stock From $895 to $795.
Could The Market Be Wrong About Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Given Its Attractive Financial Prospects?
Goldman Sachs Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Cuts Target Price to $1,185
BMO Capital Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Cuts Target Price to $950
Regeneron Pharma Is Maintained at Neutral by Citigroup
Regeneron Pharmaceuticals Analyst Ratings
A Quick Look at Today's Ratings for Regeneron Pharmaceuticals(REGN.US), With a Forecast Between $565 to $1,152
Regeneron (REGN) Gets a Buy From Bernstein
Regeneron Pharmaceuticals To Present At J.P. Morgan Healthcare Conference; Webcast At 5:15 PM ET
Live On CNBC, Rob Sechan Announces Sold Regeneron
Express News | Regeneron Pharmaceuticals Inc : Jefferies Cuts Target Price to $1,120 From $1,200
Citigroup Cuts Regeneron Pharmaceuticals' Price Target to $795 From $895
Regeneron Announces IPR&D Charges
4D Molecular Downgraded at BMO on Limited Population for Wet AMD Candidate
Regeneron Pharmaceuticals Met Primary Endpoint in Cell Carcinoma Treatment Trial
Express News | Regeneron Pharmaceuticals Shares Down 3.9% Premarket
Regeneron Stock Falls on Eylea Sales Miss
Express News | Corrected- Regeneron Q4 Eylea Hd U.S. Net Product Sales USD 305 Million (Corrects to Clarify Amount Is for Eylea Hd U.S. Net Product Sales, Not 'revenue', and Removes Incorrect Reference to Estimate)
Express News | Regeneron: To Submit Sbla for Eylea Hd for Every 4-Week Dosing, for Retinal Vein Occlusion in Q1